Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)

Abstract

Multiple myeloma is an incurable hematological malignancy that relies on drug combinations for first and secondary lines of treatment. The inclusion of proteasome inhibitors, such as bortezomib, into these combination regimens has improved median survival. Resistance to bortezomib, however, is a common occurrence that ultimately contributes to treatment failure, and there remains a need to identify improved drug combinations. We developed the quadratic phenotypic optimization platform (QPOP) to optimize treatment combinations selected from a candidate pool of 114 approved drugs. QPOP uses quadratic surfaces to model the biological effects of drug combinations to identify effective drug combinations without reference to molecular mechanisms or predetermined drug synergy data. Applying QPOP to bortezomib-resistant multiple myeloma cell lines determined the drug combinations that collectively optimized treatment efficacy. We found that these combinations acted by reversing the DNA methylation and tumor suppressor silencing that often occur after acquired bortezomib resistance in multiple myeloma. Successive application of QPOP on a xenograft mouse model further optimized the dosages of each drug within a given combination while minimizing overall toxicity in vivo, and application of QPOP to ex vivo multiple myeloma patient samples optimized drug combinations in patient-specific contexts.

Targeting Dopamine D2, Adenosine A2A, and Glutamate mGlu5 Receptors to Reduce Repetitive Behaviors in Deer Mice

“…Adenosine A 2A and glutamate mGlu 5 cascades use overlapping molecules, including mitogenactivated protein kinase and cAMP response element binding protein . It will be important to understand which pathways are beneficial to drug response and may allow advancements in drug cocktail design that show promise in other fields like cancer drug development (Rashid et al, 2018). Pharmacokinetic and pharmacodynamic analyses of this triple drug cocktail are also imperative.…”

Addressing COVID‐19 Drug Development with Artificial Intelligence

“…Importantly, the platforms that have served as foundations for the development of Project IDentif.AI have shown prior clinical successes in indications ranging from oncology to infectious diseases. Specifically, positive treatment outcomes were observed in direct ex vivo to clinical validation studies for hematologic cancer (Quadratic Phenotypic Optimization Platform [QPOP]), and the key role of dynamic clinical dosing on efficacy was further validated on an advanced solid cancer patient (CURATE.AI) . In the area of infectious diseases, low‐dose treatment for human immunodeficiency virus (HIV) was shown to mediate undetectable viral loads while opening the doors to possible downstream reductions in treatment complications arising from side effects of high‐dose therapy (CURATE.AI) …”

AI‐Enabled Parabolic Response Surface Approach Identifies Ultra Short‐Course Near‐Universal TB Drug Regimens

“…The AI‐PRS approach is a new paradigm for identifying highly synergistic drug regimens for the treatment of disease based upon the observation that drug‐dose inputs are correlated with phenotypic outputs (e.g., amelioration of a disease state) in numerous biological systems by a parabolic response surface; such a surface is described by a quadratic algebraic equation . The AI‐PRS approach, which is output driven and hence agnostic to drug mechanism, has been applied to identify synergistic drug combinations to address a large variety of medical problems including treatment of cancer (hepatocellular, breast, ovarian, colon, renal, and bladder carcinoma; multiple myeloma; acute lymphoblastic leukemia) and infectious diseases (herpes simplex virus‐1 infection; parasitic nematode infection) and suppression of rejection in liver transplantation …”